Funding Highlights
MindRank AI Secures $52M Series B to Advance AI-Native Drug Discovery
MindRank AI Ltd. has announced the completion of a $52 million Series B financing round led by a consortium of institutional and healthcare funds. The capital will accelerate the development of the company’s proprietary "Molecule Arts Platform" (MAP), an AI-native engine that integrates biological, chemical, computational, and clinical data into a unified R&D framework.
The financing will also support MindRank’s expanding pipeline, anchored by its lead program, MDR-001, an oral small-molecule GLP-1 receptor agonist currently in Phase III clinical development in China. MindRank successfully moved MDR-001 from project initiation to Phase III in approximately 4.5 years with a cumulative investment of roughly $23 million. Beyond this flagship program, the company has secured three IND clearances across the US and China, with five additional preclinical candidates nominated, underscoring the platform's ability to drive scalable, capital-efficient drug discovery and shorten development timelines.
The Results Are In: Oncology Leads
When we asked which therapy area has shaped modern medicine the most, 59% of 142 voters chose oncology. Cardiology followed at 19%, rare disease at 14%, and neurology at 8%.
The audience vote closely matched the Prix Galien USA medal data. Since 2007, oncology has received 24 medals, representing 23% of all awards and nearly one in four medals given. Cardiology follows with 14 medals, or 13%.
The results reflect just how significantly oncology has influenced research, clinical practice, diagnostics, biomarkers, treatment development, and patient care over the past two decades.
While every therapy area has played an important role in advancing medicine, both the poll results and the medal data point to oncology as the clear leader.
Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations and upcoming event.
Regulatory Updates
UK Lung Cancer Treatment Decisions and US Biosimilar Expansion
This week’s regulatory landscape highlights critical shifts in oncology and respiratory medicine. In the United Kingdom, NICE has issued draft guidance advising against routine NHS coverage for Amgen’s Lumykras (sotorasib) in treating KRAS G12C-mutated NSCLC. NICE cited insufficient evidence regarding long-term survival benefits over standard chemotherapy, despite Amgen’s insistence that real-world data supports the therapy’s clinical value. Patients currently accessing the drug via a managed access program will retain their treatment.
Conversely, the UK MHRA provided a positive boost to respiratory care by approving Boehringer Ingelheim’s Jascayd (nerandomilast) for idiopathic and progressive pulmonary fibrosis. As the first new therapy in this space in a decade, it offers a new option for patients with scarring lung diseases. Across the Atlantic, the FDA approved Accord BioPharma’s Ennumo, a biosimilar to Neulasta, marking a strategic milestone for the company’s goal to expand access to cost-effective oncology supportive care by 2030.
Industry Collaborations & Mergers
BioMed X and Boehringer Ingelheim Launch XSeed Labs Research Team for Eye Health
BioMed X and Boehringer Ingelheim have unveiled Team NIB (New Platform for Next-Generation Intraocular Biologics), a new research initiative based at XSeed Labs in Ridgefield, Connecticut. Led by molecular biologist Dr. Deniz Ugurlu Cimen, the team is tasked with developing an innovative human organotypic in vitro platform technology designed specifically to validate next-generation biologics for eye disease.
The initiative addresses a critical bottleneck in ophthalmology: the need for highly predictive models capable of testing complex drug designs. By integrating expertise in stem cell biology, biomaterials, and micro-physiological systems, Team NIB aims to build a human-based eye model that captures essential physiological features, ultimately enhancing translational success. This partnership underscores Boehringer Ingelheim’s strategic expansion into eye health and reinforces the BioMed X incubator model, which embeds external scientific talent directly within pharmaceutical R&D environments to accelerate the development of therapies for vision-threatening conditions.
Market Trends & Analysis
Door-to-door pharmaceutical deliveries poised to increase demand for airfreight transportation
A shift toward personalized, door-to-door pharmaceutical shipments, particularly for cell and gene therapies (CGT), is poised to bolster the air cargo sector, according to Cathay Cargo. As these high-value, time-sensitive therapies become more prevalent, the supply chain is experiencing increased complexity, necessitating the speed and precision that only airfreight can provide. Cathay Cargo notes that products with shelf lives measured in days rely heavily on express service and rigorous temperature-controlled logistics, creating significant opportunities for carriers. While advancements in passive packaging have prompted a shift toward ocean freight for over-the-counter pharmaceuticals, air transport remains indispensable for innovative, high-end therapeutics. Industry leaders anticipate that if current US trends in personalized medicine expand globally over the next five years, the demand for specialized, time-critical air logistics will intensify, positioning airfreight as the critical infrastructure for the future of personalized patient care.
Our Perspective
Investors Are Pouring Billions Into Not Dying – Should They Be?
The longevity biotech market is booming, currently valued at ~$30 billion in 2026, and with estimates of hitting $52 billion by 20351. But behind the money, how much of what is being promised is based on scientific evidence from real human studies? And are we actually going to see a meaningful enhancement in healthspan – the portion of an individual’s life where they are generally healthy – or is it all a fad?
In support of the longevity biotech market, there is increasing evidence supporting longevity solutions moving from the speculative to the legitimate. Longevity studies are complicated, requiring biomarkers of aging to evaluate interventions. While these have been hard to demonstrate in the past, large, long-term cohort studies are now identifying biomarkers in centenarians that may predict longer life expectancy2, and high-quality reviews suggest we may be nearing the point of aging biomarker use in clinical trials3. Machine learning is accelerating this further, both in analyzing large human datasets and in target discovery4, and the field is increasingly supported by credible institutions, academics, and Big Pharma5,6.
But is this sufficient justification for the billions of dollars that the market is worth? Skepticism around the longevity biotech market is supported by the current lack of any clinically approved longevity drug; the FDA doesn’t even recognize aging as an indication. Validated aging biomarkers, while promising, are still not widely accepted, making it difficult to assess the success of longevity-targeting therapeutics. In addition, many dramatic lifespan claims have used evidence from animal models, which so far have had limited, if any, success when tested in humans7.
While we can never truly know when the next great scientific leap forward will occur, it currently seems unlikely that any longevity-extending drugs will be available to the general public anytime soon. But that doesn’t mean that investment is completely futile; it is what has got us this far, and could be forming the basis of exciting discoveries ahead.
References
2. Murata S, Ebeling M, Meyer AC, Schmidt-Mende K, Hammar N, Modig K. Blood biomarker profiles and exceptional longevity: comparison of centenarians and non-centenarians in a 35-year follow-up of the Swedish AMORIS cohort. Geroscience. 2024;46(2):1693-1702. doi:10.1007/s11357-023-00936-w
3. Moqri M, Herzog C, Poganik JR, et al. Biomarkers of Aging for the Identification and Evaluation of Longevity Interventions. Cell. 2023;186(18):3758-3775. doi:10.1016/j.cell.2023.08.003
Upcoming Events
